ABCG2和SLC2A9在高尿酸血症和痛风发病中作用的研究进展

doi:10.16352/j.issn.1001-6325.2023.09.1467

基础医学与临床 ›› 2023, Vol. 43 ›› Issue (9): 1467-1471.doi: 10.16352/j.issn.1001-6325.2023.09.1467

ABCG2和SLC2A9在高尿酸血症和痛风发病中作用的研究进展

杨丽娟^1,2, 董秋梅^1*, 吴昊¹

1.内蒙古医科大学,内蒙古呼和浩特 010107;
2.内蒙古自治区中医医院,内蒙古呼和浩特 010020

收稿日期:2022-08-08 修回日期:2023-02-27 出版日期:2023-09-05 发布日期:2023-09-01
通讯作者: ^*d.qium@163.com
基金资助:
内蒙古自治区科技计划(2020GG0194)

Progress on the role of ABCG2 and SLC2A9 in the onset of hyperuricemia and gout

YANG Lijuan^1,2, DONG Qiumei^1*, WU Hao¹

1. Inner Mongolia Medical University, Hohhot 010107;
2. Inner Mongolia Autonomous Region Hospital of Traditional Chinese Medicine,Hohhot 010020, China

Received:2022-08-08 Revised:2023-02-27 Online:2023-09-05 Published:2023-09-01
Contact: ^*d.qium@163.com

摘要/Abstract

摘要： ABCG2和SLC2A9编码尿酸转运蛋白ABCG2和GLUT9。ABCG2单核苷酸多态性(SNP)可以使ABCG2蛋白表达减少、转运功能下降,继而引发肠道尿酸排泄功能障碍,导致血尿酸升高。SLC2A9对血尿酸的调节较为复杂,该基因功能缺失会引起肾小管尿酸重吸收减少、肠道尿酸排泄障碍和肝脏摄取尿酸障碍。ABCG2通过引起高尿酸血症(HUA)和增加炎性反应促进痛风发作。SLC2A9功能缺失反而可以减轻氧化和炎性反应。此外,ABCG2与早发痛风有着密切关系,其SNP是早发痛风的危险因素。

关键词: ABCG2, SLC2A9, 高尿酸血症, 痛风

Abstract: ABCG2 and SLC2A9 encode the uric acid transporters ABCG2 and GLUT9. ABCG2 single nucleotide polymorphism (SNP) can reduce the expression and transport function of ABCG2 protein, and then cause intestinal uric acid excretion dysfunction, resulting in the increase of blood uric acid. The regulation of blood uric acid by SLC2A9 is complicated. Loss of function of SLC2A9 may lead to decreased renal tubule uric acid reabsorption, impaired intestinal uric acid excretion and impaired hepatic uric acid uptake. ABCG2 promotes gout attacks by causing hyperuricemia(HUA) and increasing inflammatory responses. On the contray, loss of function of SLC2A9 can instead reduce oxidation and inflammatory responses. In addition, ABCG2 has a close relationship with early-onset gout and its SNP is a risk factor for early onset gout.

Key words: ABCG2, SLC2A9, hyperuricemia, gout

中图分类号:

R589.7

杨丽娟, 董秋梅, 吴昊. ABCG2和SLC2A9在高尿酸血症和痛风发病中作用的研究进展[J]. 基础医学与临床, 2023, 43(9): 1467-1471.

YANG Lijuan, DONG Qiumei, WU Hao. Progress on the role of ABCG2 and SLC2A9 in the onset of hyperuricemia and gout[J]. Basic & Clinical Medicine, 2023, 43(9): 1467-1471.

参考文献 26

[1]	Zhang M, Zhu X, Wu J, et al. Prevalence of hyperuricemia among chinese adults: findings from two nationally representative cross-sectional surveys in 2015-16 and 2018-19[J]. Front Immunol, 2022, 12: 791983. doi:10.3389/fimmu.2021.791983.
[2]	Topless RKG, Major TJ, Florez JC, et al. The compara-tive effect of exposure to various risk factors on the risk of hyperuricaemia: Diet has a weak causal effect[J]. Arthritis Res Ther, 2021, 23: 1-12.
[3]	Chang YS, Lin CY, Liu TY, et al. Polygenic risk score trend and new variants on chromosome 1 are associated with male gout in genome-wide association study[J]. Arthritis Res Ther, 2022, 24: 1-11.
[4]	Homolya L. Medically important alterations in transport function and trafficking of ABCG2[J]. Int J Mol Sci, 2021, 22: 2786. doi:10.3390/ijms22062786.
[5]	Kimura T, Takahashi M, Yan K, et al. Expression of SLC2A9 isoforms in the kidney and their localization in polarized epithelial cells[J]. PLoS One, 2014, 9: e84996. doi: 10.1371/journal.pone.0084996.
[6]	Chen IC, Chen YJ, Chen YM, et al. Interaction of alcohol consumption and ABCG2 rs2231142 variant contributes to hyperuricemia in a taiwanese population[J]. J Pers Med, 2021, 11: 1158. doi: 10.3390/jpm11111158.
[7]	Bartos Z, Homolya L. Identification of specific trafficking defects of naturally occurring variants of the human ABCG2 transporter[J]. Front Cell Dev Biol, 2021, 9: 615729. doi: 10.3389/fcell.2021.615729.
[8]	Hoque KM, Dixon EE, Lewis RM, et al. The ABCG2 Q141K hyperuricemia and gout associated variant illuminates the physiology of human urate excretion[J]. Nat Commun, 2020, 11: 2767. doi: 10.1038/s41467-020-16525-w.
[9]	Chen CJ, Tseng CC, Yen JH, et al. ABCG2 contributes to the development of gout and hyperuricemia in a genome-wide association study[J]. Sci Rep, 2018, 8: 3137. doi: 10.1038/s41598-018-21425-7.
[10]	Wrigley R, Phipps-Green AJ, Topless RK, et al. Pleiotropic effect of the ABCG2 gene in gout: involvement in serum urate levels and progression from hyperuricemia to gout[J]. Arthritis Res Ther, 2020, 22: 1-10.
[11]	Hosoyamada M. Hypothetical mechanism of exercise-induced acute kidney injury associated with renal hypouricemia[J]. Biomedicines, 2021, 9: 1847. doi: 10.3390/biomedicines9121847.
[12]	DeBosch BJ, Kluth O, Fujiwara H, et al. Early-onset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9[J]. Nat Commun, 2014, 5: 4642. doi: 10.1038/ncomms5642.
[13]	Luscher BP, Schoeberlein A, Surbek DV, et al. Hyperuricemia during pregnancy leads to a preeclampsia-like phenotype in mice[J]. Cells, 2022, 11: 3703. doi: 10.3390/cells11223703.
[14]	Lüscher BP, Albrecht C, Stieger B, et al. Glucose transporter 9 (GLUT9) plays an important role in the placental uric acid transport system[J]. Cells, 2022, 11: 633. doi: 10.3390/cells11040633.
[15]	Nie Q, Liu M, Zhang Z, et al. The effects of hyperuricemia on endothelial cells are mediated via GLUT9 and the JAK2/STAT3 pathway[J]. Mol Biol Rep, 2021, 48: 8023-8032.
[16]	Takei R, Cadzow M, Markie D, et al. Trans-ancestral dissection of urate-and gout-associated major loci SLC2A9 and ABCG2 reveals primate-specific regulatory effects[J]. J Hum Genet, 2021, 66: 161-169.
[17]	Rivera-Paredez B, Macías-Kauffer L, Fernandez-Lopez JC, et al. Influence of genetic and non-genetic risk factors for serum uric acid levels and hyperuricemia in mexicans[J]. Nutrients, 2019, 11: 1336. doi: 10.3390/nu11061336.
[18]	Lin CY, Chang YS, Liu TY, et al. Genetic contributions to female gout and hyperuricemia using genome-wide association study and polygenic risk score analyses[J]. Rheumatology (Oxford), 2023, 62: 638-646.
[19]	Sun M, Sun W, Zhao X, et al. A machine learning-assisted model for renal urate underexcretion with genetic and clinical variables among Chinese men with gout[J]. Arthritis Res Ther, 2022, 24: 1-9.
[20]	李婷婷, 李爽境, 田甜, 等. 生活方式指数与基因交互作用对凉山地区居民高尿酸血症影响[J]. 中华疾病控制杂志, 2021, 25: 37-42.
[21]	Tin A, Schlosser P, Matias-Garcia PR, et al. Epigenome-wide association study of serum urate reveals insights into urate co-regulation and the SLC2A9 locus[J]. Nat Commun, 2021, 12: 7173. doi: 10.1038/s41467-021-27198-4.
[22]	Gao Q, Cheng X, Merriman TR, et al. Trends in the manifestations of 9754 gout patients in a Chinese clinical center: a 10-year observational study[J]. Joint Bone Spine, 2021, 88: 105078. doi: 10.1016/j.jbspin.2020.09.010.
[23]	Pálinkás M, Szabó E, Kulin A, et al. Genetic polymorphisms and decreased protein expression of ABCG2 urate transporters are associated with susceptibility to gout, disease severity and renal-overload hyperuricemia[J]. Clin Exp Med, 2022. doi: 10.1007/s10238-022-00848-7.
[24]	Zaidi F, Narang RK, Phipps-Green A, et al. Systematic genetic analysis of early-onset gout: ABCG2 is the only associated locus[J]. Rheumatology (Oxford), 2020, 59: 2544-2549.
[25]	Stiburkova B, Pavelcova K, Pavlikova M, et al. The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients[J]. Arthritis Res Ther, 2019, 21: 1-10.
[26]	Toyoda Y, Pavelcová K, Bohatá J, et al. Identification of two dysfunctional variants in the ABCG2 urate transporter associated with pediatric-onset of familial hyperuricemia and early-onset gout[J]. Int J Mol Sci, 2021, 22: 1935. doi: 10.3390/ijms22041935.

ABCG2和SLC2A9在高尿酸血症和痛风发病中作用的研究进展

Progress on the role of ABCG2 and SLC2A9 in the onset of hyperuricemia and gout

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 26

相关文章 6

编辑推荐

Metrics

本文评价

[1]	代志新, 王玉敏. NLRP3炎性小体在高尿酸血症肾病中作用的研究进展[J]. 基础医学与临床, 2023, 43(2): 322-326.
[2]	高泽燕, 刘晓月, 陈丽萌, 谭莉, 张一休, 李建初, 吕珂. 超声检查在高尿酸血症患者多脏器评估中的临床应用价值[J]. 基础医学与临床, 2020, 40(4): 538-542.
[3]	董鹏, 刘伟, 满斯亮, 李宏超, 王丽芳, 宋慧. 痛风急性发作所致发热患者临床特点分析[J]. 基础医学与临床, 2020, 40(11): 1519-1522.
[4]	卢守燕马志刚黄军悦李莹屏黄文辉. 氯沙坦钾下调尿酸性肾纤维化大鼠肾小管上皮细胞尿酸转运蛋白-1的表达[J]. 基础医学与临床, 2019, 39(5): 720-725.
[5]	别志欣方卫纲黄晓明王玉朱卫国陈嘉林曾学军. 北京地区成人血清尿酸水平与代谢综合征的关系分析[J]. 基础医学与临床, 2010, 30(8): 790-794.
[6]	武文明段瑞娴. 产朊假丝酵母尿酸酶与苛求芽孢杆菌尿酸酶特性的比较[J]. 基础医学与临床, 2010, 30(4): 364-368.